. Author manuscript; available in PMC: 2014 Mar 14.

Published in final edited form as: Antibodies (Basel). 2012 Jul 4;1(2):149–171. doi: 10.3390/antib1020149

TABLE 1.

Efficacy of ch14.18-IL2 exceeds ch14.18 + IL2

Treatment	Tumor	Number of Tumor Foci
PBS IL2+ch14.18 ^**ch14.18- IL2	^NXS2 ^NXS2 ^*NXS2	>250, >250, >250, >250, 240, 115 174, 134, 105, 102, 91, 83 0, 0, 0, 0, 0, 0,
ch14.18-IL2 PBS IL2+ch14.18 ch14.18-IL2	^#B16 ^#B78 +B16 ^#B78 + B16 ^#B78 + B16	>500, >500, >500, >500, >500, 138, 97 >500, >500, >500, >500, >500, >500, >500,>500 >500, >500, >500, >500, 189, 179, 104 ^##0, 0, 2, 7, 9, 12, 21, 43

Hepatic metastases (mets) were induced with 10⁶ NXS2 cells IV into AJ mice. On day 1 mice received PBS, 10 mcg ch14.18 mAb + 30,000 IU IL2/d, or 10 mcg of ch14.18-IL2 daily×6d. Mets were scored for each of 6 mice on d21, and were less in the IC group

^**

than the other 2 groups (p < 0.001) [57];

Pulmonary mets in C57Bl mice were induced by IV injection of 1x10⁶ B16 cells (GD2-) alone, or combined with 5x10⁶ B78 cells (GD2⁺). One week post-inoculation, 7d of PBS, 8 µg ch14.18 + 24,000 IU IL-2, or 8 µg ch14.18-IL2 was initiated, and mets were scored 4 wks later.

^##

Mice with mixed tumors treated with IC had fewer mets than all other groups (p ≤ 0.002) [55].